Kim A. Papp, MD, PhD, FRCPC

K. Papp Clinical Research
135 Union Street East
Waterloo, Ontario, Canada
N2J 1C4
519-579-9535

 

Specialty: Dermatology

 

Dr. Kim Papp, Dermatologist Specialist in Psoriasis

Research Interests: Psoriasis, Psoriatic Arthritis, Acne, Actinic Keratoses, Atopic Dermatitis (Eczema), Basal Cell Carcinoma, Onychomycosis, Seborrheic Dermatitis, Vaccines


Dr. Kim Papp is a Member of the College of Physicians and Surgeons of Ontario, a Fellow of the Royal College of Physicians and Surgeons of Canada, and a Fellow of the American Academy of Dermatology.  The Waterloo, Ontario, Canada based dermatologist has over 25 years’ experience as a Principal Investigator, and has conducted over 170 psoriasis studies in which he closely supervised and assessed over 2750 subjects.  Dr. Papp is an internationally renowned Key Opinion Leader in clinical research who conducts clinical trials on a wide range of dermatological disorders.

Dr. Papp, with the support of Probity Medical Research, an organization for which he serves as Founder and President, has earned the distinction of top enrolling investigator in over 70 international dermatology studies.


Dr. Papp has conducted early through late phase psoriasis studies, and has been instrumental in the investigation and development of the following compounds:

adalimumab (Humira®), AIN457, alefacept, AMG714, AMG827, apremilast (CC-10004), BIRB 796 BS, BIRT 2584XX, BMS-582949, briakinumab (ABT-874), CD 2027, clobex, CP-690,550, CRx-140, cyclosporine, dovobet, dovonex, efalizumab, etanercept, golimumab, ILV094, infliximab, KH 1650, MEDI-507, MEDI-545, methotrexate, onercept, recombinant human interleukin eleven (rhIL-11), roziglitazone maleate, RWJ-445380,tacrolimus, tazorac, tofacitinib (CP-690, 550), ustekinumab (CNTO1275), volclosporine (ISA247)

K. Papp Clinical Research, like many high-enrolling research sites, has had routine inspections by the Food and Drug Administration, Health Canada, and the European Medicines Agency.  Dr. Papp’s clinic has the unique distinction of producing no significant findings; the FDA’s Form 483—a standard document issued to non-compliant research centres—has never been issued to K. Papp Clinical Research. 

Dr. Papp has acted as consultant and/or advisor to over 40 pharmaceutical companies on the development of dermatological compounds.  He is instrumental in improving and refining study designs, and serves on a number of Steering Committees and Advisory Boards tasked with developing effective and efficient strategies for the timely development of new treatments.  An author on over 275 publications, and a highly sought-after speaker known for delivering engaging, thought-provoking and accessible presentations, Dr. Papp is held in the highest esteem by the academic and medical communities.

 

Click to view Dr. Kim Papp's Publications

</t

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login

Gooderham M, Papp K. Clinical Trial and Registry Data. Curr Probl Dermatol 2018; 53: 15-27. Epub 2017 Nov 7. PMID: 29131034 / doi: 10.1159/000478074

Reich K, Leonardi C, Papp K, Gottlieb A, Thaçi D, Schacht A, Ball S, Agada N, Mallbris L. Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis”. J Invest Dermatol 2017 Dec; 137(12): 2642-4. Epub 2017 Aug 2. PMID: 28780085 / doi: 10.1016/j.jid.2017.06.031

Abe M, Nishigori C, Torii H, Ihn H, Ito K, Nagaoka M, Isogawa N, Kawaguchi I, Tomochika Y, Kobayashi M, Tallman AM, Papp KA. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial. J Dermatol 2017 Nov; 44(11): 1228-37. Epub 2017 Jul 17. PMID: 28714180 / doi: 10.1111/1346-8138.13956

Hong CH, Papp KA, Lophaven KW, Skallerup P, Philipp S. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol 2017 Nov; 31(11): 1876-83. Epub 2017 Sep 14. PMID: 28796913 / doi: 10.1111/jdv.14515

Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM. Ixekizumab treatment for psoriasis: Integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol 2017 Oct 9 [Epub ahead of print]. PMID: 28991370 / doi: 10.1111/bjd.16050

Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol 2017 Oct 6 [Epub ahead of print]. PMID: 28993005 / doi: 10.1016/j.jaad.2017.08.029

Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, Wu JJ, Rastogi S, Harris S, Pillai R, Israel RJ. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol 2017 Oct 3 [Epub ahead of print]. PMID: 28985956 / doi: 10.1016/j.jaad.2017.08.024

Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, Zhao Y, Parrino J, Popmihajlov Z. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: A phase 2, randomized, double-blind, placebo-controlled clinical trial. Clinical Infectious Diseases 2017 Oct 1; 65(7): 1174-82. Epub 2017 Aug 5. doi: 10.1093/cid/cix484

Lynde CW, Bourcier M, Gooderham M, Guenther L, Hong CH, Papp KA, Poulin Y, Sussman G, Vender R. A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. J Cutan Med Surg 2017 Oct 1: 1203475417733460 [Epub ahead of print]. PMID: 29082775 / doi: 10.1177/1203475417733460

Verma L, Mayba JN, Gooderham MJ, Verma A, Papp KA. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices. J Cutan Med Surg 2017 Oct 1: 1203475417733957 [Epub ahead of print]. PMID: 29056080 / doi: 10.1177/1203475417733957

Bissonnette R, Kerdel F, Naldi L, Papp K, Galindo C, Langholff W, Tang KL, Szapary P, Fakharzadeh S, Srivastava B, Goyal K, Gottlieb AB. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis. J Drugs Dermatol 2017 Oct 1; 16(10): 1002-13. PMID: 29036254

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, Saiag P, Smith CH, Dauden E, de Jong EM, Feist E, Jobling R, Maccarone M, Mrowietz U, Papp KA, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Dressler C. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2017 Sep 11 [Epub ahead of print]. PMID: 28895202 / doi: 10.1111/jdv.14454

Bissonnette R, Bourcier M, Gooderham M, Hong CH, Landells I, Lynde C, Papp K, Poulin Y, Vender R, Wiseman MC. Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. J Cutan Med Surg 2017 Sep/Oct; 21(2_suppl): 2S-40S. PMID: 29156950 / doi: 10.1177/1203475417722552

Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: A randomized, vehicle-controlled study. J Drugs Dermatol 2017 Sep 1; 16(9): 909-16. PMID: 28915286

Lima H, Gooderham M, Dutz J, Lynde C, Chapdelaine H, Ellis A, Gilbert M, Ho V, Papp K, Poulin Y, Sussman G. Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. Allergy Asthma Clin Immunol 2017 Aug 24; 13:38. eCollection 2017. PMID: 28852410 / doi: 10.1186/s13223-017-0210-0

Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, Iles J, Stolshek BS, Kaliyaperumal A, Papp KA. Open-label study of etanercept treatment in patients with moderate to severe plaque psoriasis who lost a satisfactory response to adalimumab. Br J Dermatol 2017 Aug; 177(2): 411-8. Epub 2017 Jul 19. PMID: 28196270 / doi: 10.1111/bjd.15381

Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, Rastogi S, Pillai R, Israel R. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol 2017 Aug; 77(2): 372-4. PMID: 28711089 / doi: 10.1016/j.jaad.2017.03.026

Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, Day RM, Chen R, Shah K, Ferrándiz C, Cather JC. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017 Aug; 77(2): 310-17. Epub 2017 Apr 14. PMID: 28416342 / doi: 10.1016/j.jaad.2017.01.052

Papp KA, Gooderham MJ, Girard G, Raman M, Strout V. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol 2017 Aug; 31(8): 1324-32. Epub 2017 Jun 14. PMID: 28556418 / doi: 10.1111/jdv.14313

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomised, double-blind, 52-week, phase 3 study in moderate-to-severe plaque psoriasis patients. Br J Dermatol 2017 Jul 28 [Epub ahead of print]. PMID: 28755394 / doi: 10.1111/bjd.15857

Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017 Jul 15; 390(10091): 276-88. Epub 2017 Jun 6. PMID: 28596043 / doi: 10.1016/S0140-6736(17)31279-5

Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 2017 Jul 1; 390(10089): 40-9. Epub 2017 May 4. PMID: 28478975 / doi: 10.1016/S0140-6736(17)31189-3

Papp K, Albrecht L, Barber K, Bourcier M, Dion P-L, Freiman A, Gooderham M, Guenther L, Gulliver W, Hong C, Lynde C, Poulin Y, Siddha S, Toole J, Toth D, Vender R, Wasel N, Wiseman M. An open letter to Health Canada. J Cutan Med Surg 2017; 21(3): 195-6. doi: 10.1177/1203475417704642

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B. Infections from 7 clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol 2017 Jun 10 [Epub ahead of print]. PMID: 28600810 / doi: 10.1111/bjd.15723

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017 Jun 10; 389(10086): 2287-303. Epub 2017 May 4. PMID: 28478972 / doi: 10.1016/S0140-6736(17)31191-1

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab on the treatment of patients with moderate to severe plaque psoriasisL A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017 Jun; 76(6): 1093-1102. Epub 2017 Mar 11. PMID: 28291552 / doi: 10.1016/j.jaad.2016.12.014

Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol 2017 Jun; 31(6): 1004-13. Epub 2017 Mar 31. PMID: 28190255 / doi: 10.1111/jdv.14163

Hutmacher MM, Papp K, Krishnaswami S, Ito K, Tan H, Wolk R, Valdez H, Mebus C, Rottinghaus ST, Gupta P. Evaluating dosage optimality for tofacitinib, an oral janus kinase inhibitor, in plaque psoriasis, and the influence of body weight. CPT Pharmacometrics Syst Pharmacol 2017 May; 6(5): 322-30. Epub 2017 Mar 20. PMID: 28317328  / doi: 10.1002/psp4.12182

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 2017 Apr 20; 376(16): 1551-60. PMID: 28423301 / doi: 10.1056/NEJMoa1607017

Gladman DD, Poulin Y, Adams K, Bourcier M, Barac S, Barber K, Chandran V, Dutz J, Flanagan C, Gooderham MJ, Gulliver WP, Ho VC, Hong C, Karsh J, Khraishi MM, Lynde CW, Papp KA, Rahman P, Rohekar S, Rosen CF, Russel AS, Vender RB, Yeung J, Ziouzina O, Zummer M. Treating psoriasis and psoriatic arthritis: Position paper on applying the treat-to-target concept to Canadian daily practice. J Rheumatol 2017; 44(4): 519-34.

Blauvelt A, Papp KA, Griffiths CE, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol 2017 Apr; 18(2): 273-80. PMID: 28074446 / doi: 10.1007/s40257-016-0246-9

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017 Mar; 76(3): 405-17. Epub 2017 Jan 2. PMID: 28057360 / doi: 10.1016/j.jaad.2016.11.041

Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K. Short and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol 2017 Mar; 76(3): 432-40.e17. Epub 2016 Nov 23. PMID: 27889292 / doi: 10.1016/j.jaad.2016.09.026

Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W, Hong CH, Poulin Y, Sussman G, Vender R. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2017 Jan/Feb; 21(1): 31-9. Epub 2016 Sep 22. PMID: 27635033 / doi: 10.1177/1203475416670364

Vu H TT, Gooderham M, Papp K. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol 2016 Nov; 9(11): 1423-33. Epub 2016 Oct 11. PMID: 27690669 / doi: 10.1080/17512433.2016.1242409

Alavi A, Adam DN, Alhusayan R, Boucier M, Brassard A, Coutts P, Gooderham M, Gulliver W. Hong CH, Lynde C, Marcoux D, Papp K, Poulin Y, Sibbald RG, Shear NH. Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF). J Cutan Med Surg 2016 Nov; 20(6): 613-15. PMID: 27821541

Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, Ports WC. Topical tofacitinib for atopic dermatitis: a phase IIa randomised trial. Br J Dermatol 2016 Nov; 175(5): 902-11. Epub 2016 Sep 24. PMID: 27423107 / doi: 10.1111/bjd.14871

Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, Draelos Z, Mamolo C, Purohit V, Wang C, Ports WC. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol 2016 Oct 3; 16(1): 15. PMID: 27716172 / doi: 10.1186/s12895-016-0051-4

Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W, Hong CH, Poulin Y, Sussman G, Vender R. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2016 Sep 15. [Epub ahead of print]. PMID: 27635033 / doi: 10.1177/1203475416670364

Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg 2016 Sep; 20(5): 375-431. Epub 2016 Jul 15. PMID: 27421294 / doi: 10.1177/1203475416655705

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016 Aug; 175(2): 273-86. Epub 2016 Jun 23. PMID: 26914406 / doi: 10.1111/bjd.14493

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016 Jul 28; 375(4): 3345-56. Epub 2016 Jun 8. PMID: 27299809 / doi: 10.1056/NEJMoa1512711

Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, Ports WC. Topical tofacitinib for atopic dermatitis: A Phase 2a randomised trial. Br J Dermatol 2016 Jul 16 [Epub ahead of print]. PMID: 27423107 / doi: 10.1111/bjd.14871

Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016 Jul; 75(1): 77-82.e7. Epub 2016 May 17. PMID: 27206759 / doi: 10.1016/j.jaad.2016.03.026

Gooderham M, Gavino-Velasco J, Clifford C, MacPherson A, Krasnoshtein F, Papp K. A review of psoriasis, therapies, and suicide. J Cutan Med Surg 2016 Jul; 20(4): 293-303. Epub 2016 May 5. PMID: 27207348 / doi: 10.1177/1203475416648323

Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Chavers S, Naessens D, Sermon J, Krueger GG. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol 2016 Jul; 30(7): 1148-58. Epub 2016 Mar 30. PMID: 27027388 / doi: 10.1111/jdv.13611

Muram TM, Sloan JH, Chain JS, Komocsar WJ, Meiklejohn BI, Blauvelt A, Papp K, Heffernan MP, Qian YW, Konrad RJ. A highly sensitive and drug-tolerant anti-drug antibody screening assay for ixekizumab using affinity capture elution. J Invest Dermatol 2016 Jul; 136(7): 1513-5. Epub 2016 Mar 30.PMID: 27039261 / doi: 10.1016/j.jid.2016.01.040

Papp K, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, Macias W, Zhang X, Janes JM. A randomized phase 2b trial of baricitinib, an oral Janus kinase JAK1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 2016 Jun; 174(6):1266-76. Epub 2016 Apr 5. PMID: 26800231 / doi: 10.1111/bjd.14403

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 2016 May; 74(5):841-50. Epub 2016 Feb 19. PMID: 26899199 / doi: 10.1016/j.jaad.2016.01.013

Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, Wohlrab J, Amaya-Guerra M, Kaszuba A, Nadashkevich O, Tsai TF, Gupta P, Tan H, Valdez H, Mallbris L, Tatulych S. Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials. J Drugs Dermatol 2016 May 1; 15(5):568-580. PMID: 27168266

Gooderham MJ, Poulin-Costello M, Shelton J, Bayan N, Papp KA. Predictors of topical use in psoriasis patients in the REFINE study. J Cutan Med Surg 2016 Mar; 20(2):106-12. Epub 2015 Sep 1. PMID: 26330052

Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Adalimumab efficacy in patients with psoriasis who received or did not respond to prior systemic therapy: a pooled post hoc analysis of results from three double-blind, placebo-controlled clinical trials. Am J Clin Dermatol 2016 Feb; 17(1):79-86. Epub 2015 Nov 7. PMID: 26547918 / doi: 10.1007/s40257-015-0161-5

Griffiths CE, Papp KA, Ball SG, Nickoloff BJ. Ixekizumab for psoriasis – author’s reply. Lancet 2016 Jan 16; 387(10015):226-7. Epub 2016 Jan 15. PMID: 26842297 / doi: 10.1016/S0140-6736(16)00048-9

Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016 Jan; 387(10013):40-52. Epub 2015 Oct 7. PMID: 26454361 / doi: 10.1016/S0140-6736(15)00388-8

Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on hpa axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg 2016 Jan; 20(1):44-51. Epub 2015 Jul 29. PMID: 26224733 / doi: 10.1177/1203475415597094

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015 Dec; 29(12):2277-94. Epub 2015 Oct 19. PMID: 26481193 / doi: 10.1111/jdv.13354

Bourcier M, Papp KA, Gulliver WP, Poulin Y, Barber K, Poulin-Costello M, Shelton J. Long-term management of moderate to severe plaque psoriasis patients with etanercept: a case series. J Cutan Med Surg 2015 Nov-Dec; 19(6):561-9. Epub 2015 May 7. PMID: 25951825 / doi: 10.1177/1203475415584511

Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol 2015 Nov; 73(5 Suppl 1):S19-22. PMID: 26470609 / doi: 10.1016/j.jaad.2015.07.054

Gooderham M, Papp K. Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. BioDrugs 2015 Oct; 29(5):327-39. Epub 2015 Oct 19. PMID: 26481941

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015 Oct; 173(4):949-61. PMID: 26149717 / doi: 10.1111/bjd.14018

Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol 2015 Oct; 173(4):930-9. Epub 2015 Oct 15. PMID: 26042589 / doi: 10.1111/bjd.13932

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med 2015 Oct; 373(14):1318-28. PMID: 26422722 / doi: 10.1056/NEJMoa1503824

Gooderham M, Papp K. Apremilast in the treatment of psoriasis and psoriatic arthritis. Skin Therapy Lett 2015 Sep; 20(5):1-6. PMID: 26382906

Menter A, Thaçi D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, Rubant S, Williams DA. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 2015 Sep; 73(3):410-419.e6. Epub 2015 Jul 16. PMID: 26190240 / doi: 10.1016/j.jaad.2015.06.038

Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, Zeiher B, Krueger JG. A Phase 2a randomised, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase (JAK) inhibitor, in patients with moderate to severe psoriasis. Br J Dermatol 2015 Sep; 173(3):767-76. Epub 2015 Jun 19. PMID: 25704750 / doi: 10.1111/bjd13745

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2; UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 Aug 8; 386(9993):541-51. Epub 2015 Jun 10. PMID: 26072109 / doi: 10.1016/S0140-6736(15)60125-8

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Garces K, Toole J, Poulin-Costello M. Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE. J Eur Acad Dermatol Venereol 2015 Aug; 29(8):1555-61. Epub 2015 Jan 21. PMID: 25611084 / doi: 10.1111/jdv.12934

Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 2015 Jul 1; 14(7):706-14. PMID: 26151787

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RGB, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CEM. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015 Jul; 73(1):37-49. PMID: 26089047 / doi: 10.1016/j.jaad.2015.03.049

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol 2015 Jul; 24(7):529-35. Epub 2015 May 8. PMID: 25828362 / doi: 10.1111/exd.12710

Valenzuela F, Papp KA, Pariser D, Tyring SK, Wolk R, Buonanno M, Wang J, Tan H, Valdez H. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. BMC Dermatol 2015 May 8; 15(1):8. PMID: 25951857 / doi: 10.1186/s12895-015-0025-y

Melosky B., Leighl NB., Rothenstein J., Sangha R., Stewart D., Papp K. Management of EGFR TKI–induced dermatologic adverse events. Curr Oncol 2015 Apr; 22(2):123-32. PMID: 25908911 / doi: 10.3747/co.22.2430

Papp K, Menter A, Strober B, Kricorian G, Thompson EHZ, Milmont CE, Nirula A, Klekotka P. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015 Mar; 72(3):436-439. Epub 2014 Dec 29. PMID: 25553889 / doi: 10.1016/j.jaad.2014.10.026

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Toole J, Vieira A, Poulin-Costello M. A randomized, blinded assessor study to evaluate the efficacy and safety of etanercept 50 mg once weekly plus as needed topical agent vs. etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). J Eur Acad Dermatol Venereol 2015 Feb; 29(2):361-6. Epub 2014 Jul 1. PMID: 24980988 / doi: 10.1111/jdv.12555

Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, Papp K. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Therapy Lett 2015 Feb; 20(1):1-5. PMID: 25807214

Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, Fakharzadeh S, Chevrier M, Calabro S, Langholff W, Krueger G. WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (psoriasis longitudinal assessment and registry [PSOLAR]). J Am Acad Dermatol 2015 Jan 9. [Epub ahead of print]. PMID: 25582533 / doi: 10.1016/j.jaad.2014.10.025

Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G, Nirula A, Klekotka P. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014 Dec; 71(6): 1183-1190. Epub 2014 Oct 11. PMID: 25313095 / doi: 10.1016/j.jaad.2014.08.039

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; the ERASURE and FIXTURE Study Groups. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014 Jul 24; 371(4): 326-38. Epub 2014 Jul 9.  PMID: 25007392 / doi: 10.1056/NEJMoa1314258

Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 2014 Jun; 28(6): 790-8. Epub 2013 May 17. PMID: 23679896 / doi: 10.1111/jdv.12177

Papp K, Poulin Y, Vieira A, Shelton J, Poulin-Costello M. Disease characteristics in patients with and without psoriatic arthritis treated with etanercept. J Eur Acad Dermatol Venereol 2014 May; 28(5): 581-9. Epub 2013 Mar 7. PMID: 23465037 / doi: 10.1111/jdv.12138

Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol 2014 Mar 1; 13(3): 252-6. PMID: 24595567

Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; on behalf of the PHOENIX 1 investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013 Dec; 27(12): 1535-45. Epub 2012 Dec 20. PMID: 23279003 / doi: 10.1111/jdv.12046

Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013 Nov; 169(5): 992-9. Epub 2013 Jul 16. PMID: 23855761 / doi: 10.1111/bjd.12517

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013 Nov; 69(5): 729-35. Epub 2013 Aug 24. PMID: 23981683 / doi: 10.1016/j.jaad.2013.07.023

Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guebther L, Kunynetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol 2013 Oct 1; 12(10): 1122 – 9. PMID: 24085047

Langley RG, Papp K, Gottlieb AB, Krueger GG, Williams D, Valdes J, Setze C, Strober B. Safety results from a polled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2013 Oct; 27(10): 1252-61. Epub 2012 Nov 16. PMID: 23157612 / doi: 10.1111/j.1468-3083.2012.04705.x

Papp K, Bourcier M, Ho V, Burke K, Haraoui B. Preparing for subsequent entry biologics in dermatology and rheumatology in Canada. J Cutan Med Surg 2013 Oct 1; 17(5): 340-6. PMID: 24067855

Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K. A randomised phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013 Jul; 169(1): 137-45. PMID: 23387374 / doi: 10.1111/bjd.12266

Papp K, Guenther L, Shear N, Binder C, Tan J, Lynde C, Gulliver W, Stang P. Understanding and assessing potential serious adverse events: a practical approach to understanding the benefits and harm of psoriasis treatments. J Cutan Med Surg 2013 May-Jun; 17(3):189-96. PMID:23673302

Tan H, Gupta P, Harness J, Wolk R, Chapel S, Menter A, Strober B, Langley RG, Krishnaswami S, Papp KA. Dose response and pharmacokinetics of tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of chronic plaque psoriasis. CPT: Pharmacomet Syst Pharmacol 2013 May; 2: e44. doi:10.1038/psp.2013.22

Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol 2013 May; 27(5):634-42. Epub 2012 Mar 16. PMID: 22429586

Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes 2013 May 10; 11(1):82. PMID: 23663752

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; The PHOENIX 1, PHOENIX 2, ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from five years of follow-up. Br J Dermatol 2013 Apr; 168(4):844-854. PMID: 23301632

Papp K, Poulin Y, Vieira A. Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. J Cutan Med Surg 2013 Mar-Apr; 17(2):89-105. PMID: 23582163 / doi: 10.2310/7750.2012.11126

Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013 Mar; 27(3): e376-83. Epub 2012 Oct 3. PMID: 23030767 / doi: 10.1111/j.1468-3083.2012.04716.x

Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013 Feb; 168(2):412-421. Epub 2013 Jan 18. PMID: 23106107

Wagner CL, Visvanathan S, Elashoff M, McInnes IB, Mease PJ, Krueger GG, Murphy FT, Papp K et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis 2013 Jan; 72(1):83-8. Epub 2012 Sep 12. PMID: 22975755 / doi:10.1136/annrheumdis-2012-201697

Papp K, Poulin Y, Barber K, Lynde C, Prinz JC, Berg M, Kerrouche N, Rives VP. Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis. J Eur Acad Dermatol Venereol 2012 Nov; 26(11):1407-1414. Epub 2011 Oct 27. PMID: 22032474

Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, on behalf of the PSOLAR investigators and Steering Committee. PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012 Oct; 11(10): 1210-17. PMID: 23134986

Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012 Oct; 64(10):3156-67. PMID: 22806399

Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: Results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012 Oct; 132(10):2466-9. Epub 2012 May 24. PMID: 22622425

Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey A, Hu A, Stevens R, de Vlam KL. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012 Oct; 64(10): 3156-67. Epub 2012 Jun 21. PMID: 22806399 / doi: 10.1002/art.34627

Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, Thompson EH, Hooper M, Kricorian G. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012 Sep; 167(3):649-57. PMID: 22533447

Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012 Sep; 167(3):668-77. PMID: 22924949

Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. J Eur Acad Dermatol Venereol 2012 Aug; 26(8):1007-13. Epub 2011 Oct 25. PMID: 22023702

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet 2012 Aug 25; 380(9843):738-46. Epub 2012 Jun 29.PMID: 22748702

Kavanaugh A, van der Heijde D, McInnes I, Krueger GG, Gladman D, Gómez-Reino J, Papp K et al. Golimumab, a human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: Clinical efficacy, radiographic, and safety findings through 1year of the randomized, placebo-controlled, GO-REVEAL® study. Arthritis Rheum 2012 Aug; 64(8):2504-17. PMID: 22378566

Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW. Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2012 Aug; 67(2):245-56. Epub 2011 Oct 19. PMID 22015149

Poulin Y, Wasel N, Chan D, Bernstein G, Andrew R, Fraquelli E, Papp K. Evaluating practice patterns for managing moderate to severe plaque psoriasis: Role of the family physician. Can Fam Physician 2012 Jul; 58(7):e390-e400. PMID: 22859642

Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol 2012 Jul; 67(1):e11-5. Epub 2011 Nov 21. PMID: 22101215

Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK. Biologic therapy in psoriasis: Perspectives on associated risks and patient management. J Cutan Med Surg 2012 May-Jun; 16(3):153-68. PMID: 22713438

Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012 May; 66(5):742-51. Epub 2011 Oct 5. PMID: 21978572

Haraoui B, Liu PP, Papp KA. Managing cardiovascular risk in patients with chronic inflammatory diseases. Clin Rheumatol 2012 Apr; 31(4):585-94. PMID: 22246418 / doi: 10.1007/s10067-011-1921-0

Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012 Apr; 166(4):861-72. PMID: 22356258

Haraoui B, Liu PP, Papp KA. Managing cardiovascular risk in patients with chronic inflammatory diseases. Clin Rheumatol 2012 Apr; 31(4):585-94. Epub 2012 Jan 14. PMID: 22246418

Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012 Mar; 366(13):1181-9. PMID: 22455412

Reich K, Papp KA et al. An update on the long-term safety experience of ustekinumab: Results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012 Mar; 11(3):300-12. PMID: 22395580

Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012 Feb; 66(2): 241-51. Epub 2011 Jul 14. PMID: 21752491

Papp KA, Poulin Y, Bissonnette R,  Bourcier M, Toth D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuick J. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012 Feb; 66(2):e33-e45. Epub 2010 Sep 17. PMID: 20850895

Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012 Feb; 132(2):304-14. Epub 2011 Oct 20. PMID: 22011907

Hsu S, Papp KA, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012 Jan; 148(1):95-102. PMID: 22250239

Valenzuela F, Silva P, Valdés MP, Papp K. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermosifiliogr 2011 Dec; 102(10):810-6. Epub 2011 Jun 12. PMID: 21664589

Albrecht L, Bourcier M, Ashkenas J, Papp K; Canadian Psoriasis Guidelines Committee. Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations. J Cutan Med Surg 2011 Nov-Dec; 15(6):309-21. PMID: 22202506

Hudson CP, Kempers S, Menter A, Papp K, Smith S, Sofen H, Colón LE, Johnson LA, Gottschalk R. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis 2011 Oct; 88(4):201-7. PMID:22106730

Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011 Oct 27; 365(17):1586-96. PMID: 22029980

Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011 Oct 1; 12(5):321-37. PMID: 21834597

Papp KA, Krueger GG, Jemec GBE, van de Kerkhof P, Robertson D, Estojak J, Pedersen R, Foehl J, Wajdula J, Boggs R, Molta C. Long-term, continuous dosing of etanercept in patients with plaque psoriasis. Expert Rev Dermatol 2011; 6(4):361-73.

Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J, for the Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011 Jul-Aug; 15(4):210-9. PMID: 21781627

Menter A, Sofen H, Smith S, Papp K, Kempers S, Hudson CP, Colón LE, Johnson LA, Gottschalk R. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Cutis 2011 Jul; 88(1):46-51. PMID: 21877508

Keystone EC, Papp KA, Wobeser W. Challenges in Diagnosing Latent Tuberculosis Infection in Patients Treated with Tumor Necrosis Factor Antagonists. J Rheumatol 2011 Jul; 38(7):1234-43. Epub 2011 Apr 1. PMID: 21459944

Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. J Am Acad Dermatol 2011 Apr; 64(4):671-81. PMID: 21414495

Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011 Apr; 147(4):429-36. Epub 2010 Dec 20. PMID: 21173304

Langley RG, Gupta A, Papp K, Wexler D, Osterdal ML, Cur?i? D. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: A randomized, controlled clinical trial. Dermatology 2011; 222(2):148-56. Epub 2011 Feb 3. PMID: 21293107

Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR, Gu Y, Langley RG. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011 Feb; 164(2):434-41. doi: 10.1111/j.1365-2133.2010.10139.x. PMID:21083543

Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.